Advertisement

Topics

CardiAQ Valve Technologies, Inc. Company Profile

19:16 EDT 20th March 2019 | BioPortfolio

Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary Transcatheter Mitral Valve (TMV) Implant that can be delivered through multiple delivery systems, including both Trans-femoral and Trans-apical. Through its unique anchoring mechanism that engages and utilizes the patient’s native mitral valve anatomy, physicians will be able to accurately and securely implant a new mitral valve within a beating heart, thus avoiding open-heart surgery. The CardiAQ procedures are designed to be performed in a cardiac catheterization laboratory or hybrid operating room. Ultimately, the procedure will result in less trauma to the patient and substantial potential cost-savings to the healthcare system.


News Articles [591 Associated News Articles listed on BioPortfolio]

Abbott Advances Transcath Mitral Valve Efforts With Cephea Acquisition

Abbott has exercised an option to buy Cephea Valve Technologies, developer of a minimally-invasive replacement heart valve, for an undisclosed...   

Abbott to boost heart valve therapy portfolio with acquisition of Cephea Valve Technologies

As mergers and acquisitions pick up again for the New Year, Abbott has revealed plans to buy medical device firm Cephea Valve Technologies, acting on an option it secured in 2015 with the acquisition ...

Abbott to Acquire Mitral Valve Device Maker Cephea Valve Technologies

ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately h...

Abbott to acquire Cephea Valve Technologies, Inc.

Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacem...

Abbott exercises purchase option for Cephea Valve Technologies

Abbott has exercised an option from 2015 to acquire Cephea Valve Technologies, which is developing a mitral valve replacement -More- 

Abbott All In With Cephea Valve Technologies Acquisition

Abbott has exercised an option to buy Cephea Valve Technologies, developer of a minimally-invasive replacement heart valve, for an undisclosed...   

Global Control Valve Market Forecast to 2024 - Opportunities in the Introduction of IIoT and ...

DUBLIN, Nov. 6, 2018 /PRNewswire/ -- The "Control Valve Market by Valve Type (Ball, Butterfly, Gate, Globe, Check, Plug), Valve Size, Valve Components (Actuators, Valve Read more...

Abbott to buy heart valve replacement technology developer Cephea

Cephea Valve Technologies is engaged in the development of a less-invasive heart valve replacement technology to treat people with mitral valve disease. In 2015, Abbott offered capital and The post A...

PubMed Articles [1039 Associated PubMed Articles listed on BioPortfolio]

Novel mitral valve technologies-transcatheter mitral valve implantation: a systematic review.

Valvular heart disease is an important cause of morbidity and mortality throughout the world; in industrialized nations, mitral regurgitation (MR) is the most common valvular lesion. Untreated, severe...

Transcatheter tricuspid valve intervention: a practical algorithm for patient selection.

Worldwide experience in transcatheter tricuspid valve intervention is increasing as more options become available for the treatment of severe tricuspid regurgitation. These devices can be categorized ...

Meta-analysis of Valve-in-Valve Transcatheter versus Redo Surgical Aortic Valve Replacement.

 The objective of this study was to determine whether valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) is associated with better survival than redo surgical aortic valve replacement...

Severe structural deterioration of small aortic bioprostheses treated with valve-in-valve transcatheter aortic valve implantation.

The aim of this study was to evaluate outcomes of valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) in patients with degenerated small bioprostheses.

Role of imaging in novel mitral technologies-echocardiography and computed tomography.

As minimally invasive cardiovascular procedures gain popularity, novel transcatheter mitral valve repair devices continue to emerge. The success of these technologies is critically dependent on high q...

Clinical Trials [1211 Associated Clinical Trials listed on BioPortfolio]

CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study

Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve

A Clinical Study of the CardiAQ™ TMVI System (Transapical DS)

The purpose of the study is to evaluate the initial short and long-term safety and performance of the CardiAQ™ Transcatheter Mitral Valve Implantation System using the Transapical Delive...

Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)

The purpose of the study is to generate early US feasibility data of the CardiAQ™ Transcatheter Mitral Valve Implant System. The study will enroll patients with moderate to severe mitra...

Edwards Lifesciences CardiAQ™ Transcatheter Mitral Valve Replacement (TMVR) Early Feasibility Study

Early feasibility study to evaluate the safety and function of the Edwards Lifesciences CardiAQ™ Transcatheter Mitral Valve

Observational Study of the Heart Repair Technologies Mitral Bridge in Treating Mitral Valve Regurgitation

Prospective, observational, multi-center trial in which patients with mitral regurgitation sufficient to merit mitral valve repair will receive a surgical transvalvular, intra-annular Mitr...

Companies [1350 Associated Companies listed on BioPortfolio]

CardiAQ Valve Technologies, Inc.

Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary Transcatheter Mitral Valve (TMV) Implant that can be delivered through multiple delivery syste...

CardiAQ Valve Technologies Inc.

CardiAQ Valve Technologies

Privately held CVT, headquartered in Irvine, Calif., has developed a proprietary system for Transcatheter Mitral Valve Implantation (TMVI). Through the combination of a unique anc...

Transcatheter Technologies GmbH

Transcatheter Technologies GmbH is a privately held medical device company, founded in January 2009, and headquartered in Regensburg, Germany. The Trinity transapical aortic valve system's valve p...

BioStable Science & Engineering, Inc.

BioStable Science & Engineering is a cardiovascular device company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to v...

More Information about "CardiAQ Valve Technologies, Inc." on BioPortfolio

We have published hundreds of CardiAQ Valve Technologies, Inc. news stories on BioPortfolio along with dozens of CardiAQ Valve Technologies, Inc. Clinical Trials and PubMed Articles about CardiAQ Valve Technologies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CardiAQ Valve Technologies, Inc. Companies in our database. You can also find out about relevant CardiAQ Valve Technologies, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record